改善胰岛素抵抗对2型糖尿病患者胰高血糖素样肽-1水平的影响

目的 观察2型糖尿病患者加用罗格列酮治疗后对胰高血糖素样肽-1(GLP-1)的影响。方法 用胰岛素和二甲双胍联合治疗的2型糖尿病患者共74例，随机分为观察组38例和对照组36例，观察组加用罗格列酮(4mg/d)治疗6个月后，采用酶联免疫吸附法(ELISA) 检测空腹胰高血糖素样肽-1(GLP-1)，氧化酶法检测空腹血糖( FPG)和早餐后2h血糖(2hPG)及总胆固醇(TC)和甘油三酯(TG)，柱层析法检测糖化血红蛋白(HbA1c)，化学发光法测定空腹胰岛素(FINS) 水平。观察两组干预前后FPG、 FINS、 2hPG、HbA1c、TC、TG的变化及干预后GLP-1的变化。结果 两组患者年龄、糖尿病病程、体质量指数、性别差异无统计学意义(P＞0.05)，具有可比性；观察组经罗格列酮干预6个月后，患者血清中的FPG、2hPG、FINS、HbA1c、TC、TG水平均较治疗前显著下降(P＜0.05)，空腹血清GLP-1水平较对照组升高(P＜0.05)。结论 罗格列酮可有效的降低2型糖尿病患者的血糖及HbA1c，改善胰岛素抵抗，促进空腹GLP-1分泌。

Effects of improved insulin resistance on the level of serum glucagon-like peptide-1 in type 2 diabetic patients

Objective To investigate the therapeutic effects of rosiglitazone on the level of serum glucagon-like peptide-1(GLP-1).Methods 74 type 2 diabetes patients,who were under insulin and metformin therapy,were divided into two groups: a) study group,in which 38 patients took use of insulin combined with rosiglitazone(4mg/day,orally) for 6 months;b) control group,including 36 patients.Limosis serum glucagon-like peptide-1(GLP-1),glycated hemoglobin(HbA1c),and limosis insulin(FINS) were measured by enzyme-linked-i...